<DOC>
	<DOCNO>NCT03069469</DOCNO>
	<brief_summary>This multicenter , open-label Phase 1 study DCC-3014 patient advanced malignancy , feature solid tumor , also enroll select patient acute myeloid leukemia ( AML ) , myelodysplastic syndrome ( MDS ) , acute lymphocytic leukemia ( ALL ) , chronic lymphocytic leukemia ( CLL ) . There Escalation Phase Expansion Phase study</brief_summary>
	<brief_title>Study DCC-3014 Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion Criteria ( Solid Tumor Patients ) : 1 . Patients ≥18 year age , 2 . Must progress available therapy know confer benefit disease 3 . Must tissue source tumor cell 4 . Must 1 measurable lesion accord RECIST Version 1.1 5 . Must objective evidence progression lesion previously irradiate 6 . Must ECOG performance status 01 7 . Bone Marrow Function : absolute neutrophil count ( ANC ) ≥1500/µL ; hemoglobin ≥9 g/dL ; platelet count ≥75,000/µL 8 . Hepatic Function : Total serum bilirubin ≤1.5 time upper limit normal ( ULN ; except patient know Gilbert syndrome ) ; ) ; serum aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) , ≤32.5×ULN ( ≤5×ULN presence hepatic metastasis ) 9 . Renal Function : Serum creatinine ≤1.5×ULN creatinine clearance ≥50 mL/min base either urine collection CockcroftGault estimation 10 . Coagulation Profile : Prothrombin time ( PT ) international normalize ratio ( INR ) /partial thromboplastin time ( PTT ) ≤1.5xULN5×ULN . Inclusion Criteria ( Hematologic Malignancies ) : 1 . Patients ≥18 year age , except patient ALL ≥16 year age 2 . Morphologically documented relapsed/refractory myelodysplastic syndrome ( MDS ) , acute myeloid leukemia ( AML ) , acute lymphocytic leukemia ( ALL ) , chronic lymphocytic leukemia ( CLL ) define World Health Organization ( WHO ) criteria 3 . Patients relapsed/refractory MDS , AML , ALL must progress least 1 prior therapy candidate available therapy patient rationale know confer clinical benefit 4 . For patient MDS , AML , ALL , CLL , must cell obtain either bone marrow biopsy blood collection use biomarkers may enrich DCC3014 response provide PD information 5 . For CLL , must measurable disease per International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) criterion ( Hallek criterion ) allow evaluation response 6 . May primary phagocytic malignancy include histocytoses , include Erdheim Chester Disease ( diagnose Diamond et al 2014 ) Langerhans histiocytoses eligible refractory unsuitable therapy . 7 . ECOG PS 02 8 . Bone Marrow Function : ANC ≥1000/µL ; hemoglobin ≥8 g/dL ; platelet count ≥75,000/μL . 9 . Hepatic Function : Total serum bilirubin &lt; 1.5×ULN ; serum AST ALT &lt; 2.5×ULN ( ≤5×ULN presence hepatic metastasis ) . 10 . Renal Function : Serum creatinine &lt; 2xULN1.5×ULN , glomerular filtration rate &gt; 2050 mL/hr calculate CockgroftCockroftGault formula . 11 . Serum potassium , magnesium calcium ( correct albumin ) within institutional normal limit correct supplementation . 12 . Total serum bilirubin &lt; 2xULN ( except patient know Gilbert syndrome ) . 13 . Serum AST ALT &lt; 5xULN . 14 . Coagulation Profile : Prothrombin time ( PT ) international normalize ratio ( INR ) /partial thromboplastin time ( PTT ) ≤1.5×ULN . Exclusion Criteria ( Solid Tumors ) : 1 . Treatment anticancer therapy , include investigational therapy , within 2 week prior administration study drug . For immediately prior therapy halflife longer 3 day , halflife available , interval must ≥28 day prior first administration study drug . 2 . Unresolved toxicity accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) , Version 4.03 ( ie , &gt; Grade 1 baseline ) previous anticancer therapy , exclude alopecia . 3 . The patient know active CNS metastasis . Patients previously treat brain metastasis may participate provide : They stable ( ie , without evidence progression magnetic resonance image [ MRI ] ) ≥4 week prior first dose study drug ) , All neurologic symptom return baseline , Patients require continued steroid therapy use enzymeinducing antiepileptic drug . Patients switch nonenzyme inducing antiepileptic drug . If sign symptoms suggest CNS metastasis , brain MRI must perform confirm absence detectable CNS disease within 2 week prior receive study drug . 4 . New York Heart Association class III IV heart disease , active ischemia uncontrolled cardiac condition angina pectoris , clinically significant cardiac arrhythmia require therapy , uncontrolled hypertension congestive heart failure . 5 . Systemic arterial thrombotic embolic event , cerebrovascular accident ( include ischemic attack ) hemoptysis within 6 month prior start study drug . 6 . Systemic venous thrombotic event ( eg , deep vein thrombosis ) pulmonary arterial event ( eg , pulmonary embolism ) within 1 month prior start study drug . Patients venous thrombotic event start study drug stable anticoagulation therapy eligible . 7 . Baseline prolongation ratecorrected QT interval base repeat demonstration QT interval correct ( QTc ) &gt; 450 m history long QTc syndrome . 8 . Left ventricular ejection fraction ( LVEF ) &lt; 50 % . 9 . Concurrent treatment protonpump inhibitor . Other medication increase gastric pH , ie , histamine H2 receptor antagonist antacid may take provide administer within 2 hour administration study drug . 10 . Major surgery within 2 week first dose study drug ; follow major surgery &gt; 2 week prior first dose study drug , surgical wound must heal free infection dehiscence . 11 . Any clinically significant comorbidities , uncontrolled pulmonary disease , active infection , condition , judgment Investigator , could compromise compliance protocol , interfere interpretation study result , predispose patient safety risk . 12 . Malabsorption syndrome illness could affect oral absorption . 13 . Known human immunodeficiency virus , active hepatitis B , active hepatitis C , active mycobacterium tuberculosis infection . 14 . If female , patient pregnant lactating . 15 . Known allergy hypersensitivity component study drug . 16 . Patients know Gilbert 's disease . Exclusion Criteria ( Hematologic Malignancies ) : 1 . Concurrent active malignancy expect survival less 1 year . 2 . Graft versus host disease ( GVHD ) wellcontrolled stable treatment regimen least 3 week prior initial dose study drug . 3 . Cancerdirected therapy within 2 week prior start treatment , exception hydroxyurea , allow control white blood cell count . 4 . History , current , central nervous system involvement MDS , AML , CLL . 5 . Systemic arterial thrombotic embolic event , cerebrovascular accident ( include ischemic attack ) hemoptysis within 2 month prior start study drug . 6 . Systemic venous thrombotic event ( eg , deep vein thrombosis ) pulmonary arterial event ( eg , pulmonary embolism ) within 1 month prior start study drug . Patients venous thrombotic event start study drug stable anticoagulation therapy eligible . 7 . Clinically significant coagulation disorder , disseminate intravascular coagulation . 8 . New York Heart Association class III IV heart disease , active ischemia uncontrolled cardiac condition angina pectoris , clinically significant cardiac arrhythmia require therapy , uncontrolled hypertension congestive heart failure . 9 . Baseline prolongation ratecorrected QT interval base repeat demonstration QTc &gt; 450 ms history long QTc syndrome . 10 . LVEF &lt; 50 % . 11 . Concurrent treatment protonpump inhibitor . 12 . Major surgery within 2 week first dose study drug ; follow major surgery &gt; 2 week prior first dose study drug , surgical wound must heal free infection dehiscence . 13 . Any clinically significant comorbidities , uncontrolled pulmonary disease , active infection , condition , judgment Investigator , could compromise compliance protocol , interfere interpretation study result , predispose patient safety risk . 14 . Malabsorption syndrome illness could affect oral absorption . 15 . Known human immunodeficiency virus , active hepatitis B , active hepatitis C , active cytomegalovirus ( CMV ) , active mycobacterium tuberculosis infection . 16 . Active infection wellcontrolled antibacterial antiviral therapy . 17 . If female , patient pregnant lactating . 18 . Known allergy hypersensitivity component study drug . 19 . Diagnosis acute promyelocytic leukemia ( APL , AML M3 subtype ) . 20 . Unwillingness receive infusion blood product . 21 . Patients know Gilbert 's disease .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CSF1R</keyword>
	<keyword>ALL</keyword>
	<keyword>CML</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
</DOC>